Top Markets
Coin of the day
AB Science S.A. AB Science S.A.

AB Science S.A.

AB
Rang in aandelen #24478
AB Science S.A. is a pharmaceutical company dedicated to the discovery,... AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhibitor, is currently undergoing late-stage (Phase III) clinical investigations for a range of serious conditions including prostate cancer, pancreatic cancer, amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer's disease, severe asthma, and mastocytosis. Additionally, masitinib is being evaluated in Phase II clinical trials for the treatment of Covid-19. The company's pipeline also features AB8939, a synthetic microtubule destabilizer aimed at treating acute myeloid leukemia, and AB20001, which is in Phase 2 trials to assess the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients experiencing moderate to severe COVID-19. Masitinib is sold under the brand name Masivet in the European market. AB Science S.A. was founded in 2001 and is based in Paris, France.
Aandeelprijs
$0.82200553
Marktkapitalisatie
$60.21M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-45.55%
Land
FR
Handel AB Science S.A. (AB)

Categorie

P/B-ratio voor AB Science S.A. (AB)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van AB Science S.A. is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor AB Science S.A. van 2026 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/B-ratio voor vergelijkbare bedrijven of concurrenten